Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.
Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.
复制标题
头颈部鳞状细胞癌的治疗方法-临床试验的最新进展。
DOI：
10.1016/j.tranon.2022.101426
复制
发表时间：
2022-07
影响因子：
5
通讯作者：
Khattri, Arun
中科院分区：
文献类型：
--
作者：
Goel, Bharat;Tiwari, Anoop Kumar;Pandey, Rajeev Kumar;Singh, Akhand Pratap;Kumar, Sujeet;Sinha, Abhishek;Jain, Shreyans K.;Khattri, Arun
烟草消费和感染高危人乳头瘤病毒（HPV）是头颈部鳞状细胞癌（HNSCC）的主要危险因素。在目前的临床试验中，用于治疗HNSCC的三种主要治疗方法包括化疗、分子靶向治疗和免疫治疗。免疫疗法已成为治疗HNSCC最有希望的治疗选择。目前，美国fda已经批准了三种单克隆抗体，即西妥昔单抗、派姆单抗和纳武单抗。头颈部鳞状细胞癌（HNSCC）是第六大最常见的非皮肤癌，烟草消费和感染高危人乳头瘤病毒（HPV）是主要危险因素。尽管许多治疗方法都取得了进展，但HNSCC的存活率并没有显著提高；大量临床结果表明，联合治疗策略（最著名的多西紫杉醇、顺铂和5-氟尿嘧啶）是最有效的治疗选择。针对免疫检查点的免疫疗法正在许多临床试验中进行测试，要么单独使用，要么与化疗药物或靶向治疗药物联合使用。各种单克隆抗体，如西妥昔单抗和贝伐单抗，分别靶向EGFR和VEGFR，以及其他信号通路抑制剂，如替西莫司和雷帕霉素，也正在研究用于治疗HNSCC。在本研究中，我们回顾了正在进行的临床研究中的主要靶点，特别关注所使用的药物和药物靶点。
Tobacco consumption and infection with high-risk human papillomavirus (HPV) are the major risk factors of the Head and neck squamous cell carcinoma (HNSCC). In current clinical trials the three main therapeutic approaches being employed for the treatment of HNSCC include Chemotherapy, Molecular Targeted Therapy and Immunotherapy. Immunotherapy has emerged as the most promising treatment of choice for the treatment of HNSCC. Currently, three monoclonal antibodies viz. cetuximab, pembrolizumab, and nivolumab have been approved by USFDA for the same. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably; a vast number of clinical outcomes have demonstrated that a combination strategy (the most well-known docetaxel, cisplatin, and 5-fluorouracil) is the most effective treatment choice. Immunotherapy that targets immunological checkpoints is being tested in a number of clinical trials, either alone or in conjunction with chemotherapeutic or targeted therapeutic drugs. Various monoclonal antibodies, such as cetuximab and bevacizumab, which target the EGFR and VEGFR, respectively, as well as other signaling pathway inhibitors, such as temsirolimus and rapamycin, are also being studied for the treatment of HNSCC. We have reviewed the primary targets in active clinical studies in this study, with a particular focus on the medications and drug targets used.
登录
查看更多内容
影响因子：
51.1
作者：
Cohen, Ezra E. W.;Davis, Darren W.;Karrison, Theodore G.;Seiwert, Tanguy Y.;Wong, Stuart J.;Nattam, Sreenivasa;Kozloff, Mark F.;Clark, Joseph I.;Yan, Duen-Hwa;Liu, Wen;Pierce, Carolyn;Dancey, Janet E.;Stenson, Kerstin;Blair, Elizabeth;Dekker, Allison;Vokes, Everett E.
通讯作者：
Vokes, Everett E.
影响因子：
158.5
作者：
Bernier, J;Domenge, C;van Glabbeke, M
通讯作者：
van Glabbeke, M
DOI：
10.2349/biij.2.1.e19
发表时间：
2006-01-01
期刊：
Biomedical imaging and intervention journal
影响因子：
--
作者：
Cheung, Ky
通讯作者：
Cheung, Ky
DOI：
10.1158/1078-0432.ccr-14-1298
发表时间：
2014-11-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
de Biasi AR;Villena-Vargas J;Adusumilli PS
通讯作者：
Adusumilli PS
影响因子：
1.6
作者：
Chen Z;Xu XH
通讯作者：
Xu XH